What is Carisma Therapeutics Inc (CARM)?

Carisma Therapeutics Inc（CARM）股票分析

$0.154

-0.067 (-43.81%)收盘时

Loading chart…

High: 0.170
Open: 0.159
VWAP: 0.16
Vol: 17.54M
Mkt Cap: 53.17M
Low: 0.147
Amount: 2.75M
EV/EBITDA, TTM: 0.00

Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on macrophage engineering to develop transformative therapies to treat serious diseases including liver fibrosis and cancer. The Company seeks to apply the ability to engineer macrophages and monocytes, either in vivo or ex vivo. Its proprietary chimeric antigen receptor macrophages(CAR-M) platform uses CARs to redirect macrophages or monocytes against specific tumor associated antigens with the goal of targeted antitumor immunity. It is developing a pipeline of product candidates which includes CT-1119, In Vivo CAR-Macrophage: GPC3+ Solid Tumors, In Vivo CAR-Macrophage: Oncology Targets, and CT-2401 (Liver Fibrosis). CT-2401 is a product candidate in development for liver fibrosis, and CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others.

sesenbio.com

估值指标

The current forward P/E ratio for Carisma Therapeutics Inc (CARM) is -0.38, compared to its 5-year average forward P/E of -1.34.

Forward P/E

Overvalued

5Y Average P/E

-1.34

Current P/E

-0.38

高估

-0.48

低估

-2.20

Forward EV/EBITDA

Strongly Undervalued

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

高估

0.00

低估

0.00

Forward P/S

Fair

5Y Average P/S

9.54

Current P/S

0.77

高估

22.91

低估

-3.82

Alphio AI Price Scenarios for CARM

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

Bull

Bull · 25%CARM

$0.26

情景价格

Base

Base · 50%CARM

$0.24

情景价格

Bear

Bear · 25%CARM

$0.18

情景价格

事件时间线

2026-06-02 (ET)